share_log

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD

EHare宣佈MetaHealthU將進入市場,重點是HPPD
GlobeNewswire ·  2022/04/19 20:35

MIAMI, April 19, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and bio-markers to target the condition. HPPD, (HPPD) or "flashbacks" is the only recognized long-term complication of hallucinogen use. It can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. As psychedelics become more widely accepted, the data and biomarkers from Ehave's MetaHealthU will enhance research into HPPD, which will assist medical and mental health professionals diagnose if an individual is genetically predisposed to suffer from the condition.

邁阿密,2022年4月19日(環球網)--領先的醫療保健服務和技術公司eHave,Inc.(場外交易代碼:EHVVF)(以下簡稱“公司”)今天宣佈,其MetaHealthU移動應用程序平臺將專注於確定致幻劑持續型知覺障礙(HPPD)的原因並尋找可能的治療方法。EHave開創了HPPD研究的先河,通過與墨爾本大學的合作推出了一系列研究,以收集數據和生物標記物來針對這種情況。HPPD(HPPD)或“閃回”是唯一公認的使用迷幻劑的長期併發症。它可以使一個人不斷地重温由致幻藥物引起的體驗的視覺元素。隨着迷幻藥越來越被人們接受,來自eHave‘s MetaHealthU的數據和生物標記物將加強對HPPD的研究,這將幫助醫療和精神衞生專業人員診斷一個人是否有遺傳傾向患有這種疾病。

MetaHealthU is a mobile application platform that empowers individuals to take complete control of their health and their healthcare data. One component of MetaHealthU is its digital wallet connectivity with blockchain, which enables users to bundle and share their health records in a secure and seamless way. Ehave chose blockchain for its MetaHealthU platform since it increases trust, security, transparency, and the traceability of data shared across a business network — and delivers cost savings with new efficiencies. Ehave has partnered with BurstIQ, the leading provider of blockchain-based data solutions for the healthcare industry, to use its privacy-protecting technology to protect the personal information of MetaHealthU users.

MetaHealthU是一個移動應用程序平臺,使個人能夠完全控制自己的健康和醫療保健數據。MetaHealthU的一個組件是其與區塊鏈的數字錢包連接,使用户能夠以安全和無縫的方式捆綁和共享他們的健康記錄。EBay為其MetaHealthU平臺選擇了區塊鏈,因為它提高了在企業網絡中共享的數據的可信性、安全性、透明度和可跟蹤性,並以新的效率節省了成本。EHave已與醫療行業領先的基於區塊鏈的數據解決方案提供商BurstIQ合作,使用其隱私保護技術來保護MetaHealthU用户的個人信息。

With MetaHealthU, users can securely track their health data from wearables, Electronic Health Records Systems (EHRs), Doctors and Medical Labs. It includes a "digital file cabinet" for medical records, which is ideal for research into HPPD. Users can log into their patient portals on various healthcare systems and medical labs and download their medical records in the digital file cabinet, which empowers individuals to take complete control of their health and their healthcare data. As Ehave progresses in its partnership with the University of Melbourne, the Company plans to create bio lines and a testing revenue model, as well as screening products based on MetaHealthU that are capable of indicating HPPD.

有了MetaHealthU,用户可以安全地跟蹤他們來自可穿戴設備、電子健康記錄系統(EHR)、醫生和醫療實驗室的健康數據。它包括一個用於存放病歷的“數字檔案櫃”,這是研究HPPD的理想選擇。用户可以登錄到他們在各種醫療系統和醫療實驗室上的患者門户網站,並將他們的醫療記錄下載到數字文件櫃中,這使個人能夠完全控制自己的健康和醫療保健數據。隨着eHave與墨爾本大學夥伴關係的進展,該公司計劃創建BIO系列和測試收入模式,並篩選基於MetaHealthU的能夠指示HPPD的產品。

Currently, researchers at the University of Melbourne have completed the necessary documents required for university ethics approval for online study of HPPD. The pilot study will begin sometime late in the second quarter, or the beginning of the third quarter. The researchers have also submitted a full ethics application, and are awaiting a decision on minimal risk accreditation. They have received preliminary approval for the pilot project to be considered "low or negligible risk," and received ethics board review feedback on the submission seeking clarification on the role of funders regarding data, as well as minor clarifications on surveys/tasks being used.

目前,墨爾本大學的研究人員已經完成了在線研究HPPD所需的大學倫理批准所需的文件。試點研究將在第二季度末或第三季度初的某個時候開始。研究人員還提交了一份完整的道德申請,正在等待關於最低風險認證的決定。他們已獲得初步批准,將試點項目視為“低風險或可忽略的風險”,並收到倫理委員會對提交的意見的審查反饋,要求澄清資助者在數據方面的作用,並對正在使用的調查/任務作出輕微澄清。

Ben Kaplan, CEO of Ehave, said, "Ehave has set a very aggressive goal to be the industry leader in preventing negative side effects during treatment for mental health issues. Our goal is to be the Company that prevents individuals from suffering from a lifetime of flashbacks after being treated for mental health issues with these powerful molecules. We believe individuals are genetically predisposed to HPPD, which is why we will be conducting a large-scale genetic analysis to isolate an individuals' risk profile. Ehave's engineers have integrated a series of visual processing tests into MetaHealthU to measure HPPD objectively. Under medical supervision psychedelics are extremely safe. We believe focusing Ehave's MetaHealthU mobile application platform on determining the cause and finding a possible cure for HPPD will lead to a better understanding of these molecules as a whole."

EHave首席執行官本·卡普蘭説:“eHave制定了一個非常積極的目標,即成為預防心理健康問題治療過程中的負面副作用的行業領導者。我們的目標是成為一家公司,防止個人在接受這些強大分子的精神健康問題治療後一生遭受閃回之苦。我們相信個人在基因上容易患上HPPD,這就是為什麼我們將進行大規模的基因分析來隔離個人的風險概況。EHave的工程師將一系列視覺處理測試集成到MetaHealthU中,以客觀地測量HPPD。在醫療監督下,迷幻劑是極其安全的。我們相信,將eHave的MetaHealthU移動應用平臺集中在確定HPPD的原因和找到可能的治療方法上,將使我們對這些分子作為一個整體有更好的瞭解。

Individuals with HPPD have recurring visual disturbances that only recall the part of the psychedelic experience that involved visions, which can cause anxiety and affect a person's vision. HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. As many as 5% of LSD users report some version of HPPD and serious cases could be as frequent as 1 in every 100 users of psychedelics. The market for an HPPD cure extends far beyond simple psychedelics.

患有HPPD的人有反覆出現的視力障礙,只回憶起涉及視力的迷幻經歷的一部分,這可能會導致焦慮並影響人的視力。HPPD最常見的原因是LSD和蘑菇,但也可以由MDMA、大麻,甚至SSRIs引起。多達5%的LSD使用者報告了某種版本的HPPD,嚴重病例的發生率可能高達每100名迷幻劑使用者中就有1人。HPPD療法的市場遠遠超出了簡單的迷幻藥。

About Ehave, Inc.

關於eHave公司

Ehave is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with our network of scientists and mental health professionals, we are on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. Ehave's operations span across the entire USA, Canada, Jamaica, and Australia. Additional information on Ehave can be found on the Company's website at: .

EHave是一家領先的醫療服務和技術公司,專注於通過設計新的化合物和新的治療方案來治療大腦健康,從而促進迷幻藥物到治療的進展。我們與我們的科學家和精神健康專業人員網絡一起,肩負着為患者創造安全有效的治療方法的使命,以解決大量的精神健康問題,利用臨牀數據幫助我們實現最佳的患者結果。EHave的業務遍及整個美國、加拿大、牙買加和澳大利亞。欲瞭解更多有關eHave的信息,請訪問公司網站:

Forward-Looking Statement Disclaimer

前瞻性聲明免責聲明

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

本新聞稿包含“1995年私人證券訴訟改革法”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設,會受到各種已知和未知的風險和不確定性的影響,其中許多風險和不確定性是公司無法控制的,無法預測或量化,因此,實際結果可能與此類前瞻性陳述中明示或暗示的結果大不相同:(1)公司研究、製造和其他開發工作的發起、時間、進展和結果;(2)公司推進其產品成功完成開發和商業化的能力;(3)製造、開發、商業化的能力;(3)公司的能力。, (V)公司行業內具有競爭力的公司和技術以及引入競爭產品的能力;(Vi)公司建立和維持公司合作的能力;(Vii)主要管理人員的流失;(Viii)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力;(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律;以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求,否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更多詳細信息,包含在eHave,Inc.於2015年9月24日提交給美國證券交易委員會(美國證券交易委員會)的經修訂的F-1表格註冊説明書中的“風險因素”標題下,該説明書可在美國證券交易委員會的網站上獲得。

For Media and Investor Relations, please contact:

媒體和投資者關係,請聯繫:

David L. Kugelman

大衞·L·庫格曼

(866) 692-6847 Toll Free - U.S. & Canada

(866)692-6847免費-美國和加拿大

(404) 281-8556 Mobile and WhatsApp

(404)281-8556移動電話和WhatsApp

Email: Ir@Ehave.com

電子郵件:ir@ehave.com

Skype: kugsusa

Skype:kugsusa

LinkedIn: 

LinkedIn:


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論